Back to Search
Start Over
Hypoxia‐inducible factor 1A inhibition overcomes castration resistance of prostate tumors.
- Source :
- EMBO Molecular Medicine; 6/7/2023, Vol. 15 Issue 6, p1-12, 12p
- Publication Year :
- 2023
-
Abstract
- Androgen deprivation therapy (ADT) is a cornerstone of prostate cancer (PCa) management. Although tumors initially regress, many progress to a hormone‐independent state termed castration‐resistant PCa (CRPC), for which treatment options are limited. We here report that the major luminal cell population in tumors of Pten(i)pe−/− mice, generated by luminal epithelial cell‐specific deletion of the tumor suppressor PTEN after puberty, is castration‐resistant and that the expression of inflammation and stemness markers is enhanced in persistent luminal cells. In addition, hypoxia‐inducible factor 1 (HIF1) signaling, which we have previously demonstrated to be induced in luminal cells of Pten(i)pe−/− mice and to promote malignant progression, is further activated. Importantly, we show that genetic and pharmacological inhibition of HIF1A sensitizes Pten‐deficient prostatic tumors to castration and provides durable therapeutic responses. Furthermore, HIF1A inhibition induces apoptotic signaling in human CRPC cell lines. Therefore, our data demonstrate that HIF1A in prostatic tumor cells is a critical factor that enables their survival after ADT, and identify it as a target for CRPC management. Synopsis: Resistance development to androgen deprivation therapy (ADT) in prostate cancer (PCa) patients is a major clinical issue. By analysing PCa mouse models, we found that HIF1A promotes androgen deprivation‐induced luminal cell plasticity and that its inhibition overcomes ADT resistance. Luminal‐C cells, the major epithelial subset in Pten‐deficient tumors, are intrinsically castration‐resistant.Single‐cell analyses revealed that HIF1 signaling is further activated in luminal‐C cells by castration, mediates a high plasticity state and induces resistance to ADT.HIF1A inhibition sensitizes castration‐resistant prostatic tumors to androgen deprivation and leads to long‐term therapeutic responses.ADT combined with HIF1A inhibition is a promising approach to treat castration‐resistant prostate cancer. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 17574676
- Volume :
- 15
- Issue :
- 6
- Database :
- Complementary Index
- Journal :
- EMBO Molecular Medicine
- Publication Type :
- Academic Journal
- Accession number :
- 164153871
- Full Text :
- https://doi.org/10.15252/emmm.202217209